Comments
Gujarat Themis Biosyn reported a net profit of ₹11.69 crore in the fourth quarter ended March, 2023, as against profit of ₹9.79 crore in Q4 FY22. Revenue from operations remained almost flat at ₹28.17 crore compared ₹28.76 crore.
The company’s yearly net profit surged to ₹57.97 crore from ₹43.62 crore in the previous year. Revenue from operations jumped 29.7% to ₹148.97 crore.
Gujarat Themis Biosyn (GTB) was incorporated in 1981 as a joint sector company by GIIC Ltd. and Chemosyn (P) Ltd. It commenced production in August 1985. The company is focused on pharmaceuticals. GTB was subsequently taken over by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG).
PBG a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (a JV company of Gedeon Richter Ltd, Hungary) since 2007.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.